CY1121377T1 - Θεραπευτικα εμβολια hpv16 - Google Patents

Θεραπευτικα εμβολια hpv16

Info

Publication number
CY1121377T1
CY1121377T1 CY20181101210T CY181101210T CY1121377T1 CY 1121377 T1 CY1121377 T1 CY 1121377T1 CY 20181101210 T CY20181101210 T CY 20181101210T CY 181101210 T CY181101210 T CY 181101210T CY 1121377 T1 CY1121377 T1 CY 1121377T1
Authority
CY
Cyprus
Prior art keywords
hpv
therapeutic vaccines
protein
nucleic acid
hpv16
Prior art date
Application number
CY20181101210T
Other languages
English (en)
Inventor
Evelien M BUNNIK
Jerôme H H V CUSTERS
Gerrit Ch SCHEPER
Koen OOSTERHUIS
Taco Gilles UIL
Selina KHAN
Original Assignee
Janssen Vaccines & Prevention B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52020908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121377(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Vaccines & Prevention B.V. filed Critical Janssen Vaccines & Prevention B.V.
Publication of CY1121377T1 publication Critical patent/CY1121377T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)

Abstract

Η εφεύρεση παρέχει σχεδιασμένα κατασκευάσματα νουκλεϊκού οξέος και πολυπεπτίδια που μπορούν να χρησιμοποιηθούν ως θεραπευτικά εμβόλια κατά του HPV 16. Τα πολυπεπτίδια αυτά περιλαμβάνουν ουσιαστικά όλους τους πιθανούς επίτοπους Τ-κυττάρων των ογκοπρωτεϊνών Ε6 και Ε7 του HPV 16, παρ' όλα αυτά έχουν σημαντικά μειωμένη (σε σύγκριση με το wt Ε6 και Ε7), έως και μη-ανιχνεύσιμη, μετασχηματιστική δραστικότητα, περιλαμβάνοντας θραύσματα των πρωτεϊνών Ε6 και Ε7 τα οποία έχουν αναδιαταχθεί, ενώ ταυτόχρονα περιέχουν έναν ελαχιστοποιημένο αριθμό ανεπιθύμητων νέο-επιτόπων. Η εφεύρεση παρέχει ένα μόριο νουκλεϊκού οξέος που κωδικοποιεί ένα πολυπεπτίδιο, το οποίο περιλαμβάνει μία αλληλουχία όπως εκτίθεται στη SEQ ID NO: 1. Σε ορισμένες υλοποιήσεις, το κωδικοποιημένο πολυπεπτίδιο περιλαμβάνει περεταίρω έναν τουλάχιστον επίτοπο της πρωτεΐνης Ε2 του ιού ανθρώπινων θηλωμάτων (HPV), για παράδειγμα μία πρωτεΐνη HPV 16 Ε2.
CY20181101210T 2014-11-04 2018-11-15 Θεραπευτικα εμβολια hpv16 CY1121377T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14191660 2014-11-04
PCT/EP2015/075516 WO2016071306A1 (en) 2014-11-04 2015-11-03 Therapeutic hpv16 vaccines

Publications (1)

Publication Number Publication Date
CY1121377T1 true CY1121377T1 (el) 2020-05-29

Family

ID=52020908

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181101210T CY1121377T1 (el) 2014-11-04 2018-11-15 Θεραπευτικα εμβολια hpv16

Country Status (33)

Country Link
US (4) US9701721B2 (el)
EP (2) EP3421046A1 (el)
JP (2) JP6325751B2 (el)
KR (1) KR20170083562A (el)
CN (1) CN107075521B (el)
AR (1) AR102527A1 (el)
AU (2) AU2015341926B2 (el)
BR (1) BR112017009177A2 (el)
CA (1) CA2965562C (el)
CL (1) CL2017001089A1 (el)
CO (1) CO2017004838A2 (el)
CY (1) CY1121377T1 (el)
DK (1) DK3215187T3 (el)
EA (1) EA035461B1 (el)
ES (1) ES2697903T3 (el)
HR (1) HRP20181895T1 (el)
HU (1) HUE040440T2 (el)
IL (1) IL251895B (el)
LT (1) LT3215187T (el)
MA (2) MA40902B1 (el)
MD (1) MD3215187T2 (el)
MX (1) MX2017005788A (el)
MY (1) MY181175A (el)
NZ (1) NZ730802A (el)
PL (1) PL3215187T3 (el)
PT (1) PT3215187T (el)
RS (1) RS58080B1 (el)
SA (1) SA517381457B1 (el)
SG (1) SG11201702997YA (el)
SI (1) SI3215187T1 (el)
TW (2) TWI694147B (el)
WO (1) WO2016071306A1 (el)
ZA (1) ZA201703055B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3215187T3 (pl) 2014-11-04 2019-04-30 Janssen Vaccines & Prevention Bv Szczepionki terapeutyczne HPV16
AU2016309743B2 (en) 2015-08-20 2019-02-07 Janssen Vaccines & Prevention B.V. Therapeutic HPV18 vaccines
CN109922829A (zh) 2016-05-02 2019-06-21 扬森疫苗与预防公司 治疗性hpv疫苗组合
CN106632694B (zh) * 2017-01-24 2021-02-12 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用
KR20200057742A (ko) 2017-09-23 2020-05-26 베링거잉겔하임베트메디카게엠베하 파라믹소바이러스과 발현 시스템
US20200399348A1 (en) * 2018-02-20 2020-12-24 Emory University HPV Proteins, Antibodies, and Uses in Managing Abnormal Epithelial Cell Growth
CR20200461A (es) * 2018-03-12 2021-03-11 Sqz Biotechnologies Co Método para tratar las enfermedades asociadas al vph
EP3810277A1 (en) 2018-07-20 2021-04-28 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing zika antigen with improved productivity
CN108992665B (zh) * 2018-08-06 2021-11-19 南京颂悦生物科技有限公司 基于重组减毒单增李斯特菌的宫颈癌治疗性疫苗
CN108939064B (zh) * 2018-08-06 2021-12-10 南京颂悦生物科技有限公司 基于重组减毒绵羊李斯特菌的宫颈癌治疗性疫苗
CA3128973A1 (en) 2019-03-04 2020-09-10 Bhaskar Bhattacharyya Data compression and communication using machine learning
WO2021053207A1 (en) 2019-09-20 2021-03-25 Transgene Combination of a poxvirus encoding hpv polypeptides and il-2 with an anti-pd-l1 antibody
US20230277645A1 (en) * 2020-04-02 2023-09-07 Inovio Pharmaceuticals, Inc. Compositions and methods for treating vulvar dysplasia
JP2023521194A (ja) 2020-04-13 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用
WO2021228816A1 (en) * 2020-05-12 2021-11-18 Janssen Vaccines & Prevention B.V. Administration of homologous adenoviral vectors
CN117203221A (zh) 2020-11-24 2023-12-08 牧周·乔·马 用于人类乳突病毒的dna疫苗及其使用方法
AU2022371672A1 (en) * 2021-10-22 2024-05-16 Inovio Pharmaceuticals, Inc. Compositions and methods for treating anal high-grade squamous intraepithelial lesion (hsil)

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
JP2000509614A (ja) 1997-03-04 2000-08-02 バクスター インターナショナル インコーポレイテッド アデノウイルスｅ１−相補性細胞系
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
ES2354578T3 (es) 1999-05-17 2011-03-16 Crucell Holland B.V. Adenovirus recombinante humano de serotipo ad26.
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
EP2100620A1 (en) * 1999-09-16 2009-09-16 Eisai Corporation of North America Nucleic acids encoding polyepitope polypeptides
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
CA2425152A1 (en) 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
DE60116371T3 (de) 2000-11-23 2016-11-17 Bavarian Nordic A/S Variante des modifizierten vaccinia ankara virus
WO2002088346A2 (en) 2001-05-01 2002-11-07 National Research Council Of Canada A system for inducible expression in eukaryotic cells
MXPA04008891A (es) 2002-04-25 2004-11-26 Crucell Holland Bv Medios y metodos para la produccion de vectores de adenovirus.
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
WO2005089164A2 (en) * 2003-12-31 2005-09-29 Pharmexa Inc. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
CN1922308A (zh) 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
EA010863B1 (ru) 2004-11-08 2008-12-30 Хромагеникс Б.В. Отбор клеток-хозяев, экспрессирующих белок на высоких уровнях
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
NZ571010A (en) 2006-02-28 2010-11-26 Vaxart Inc Chimeric adenoviral vectors with toll-like receptor-3 (TLR-3) agonists
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
ATE518958T1 (de) * 2007-01-30 2011-08-15 Transgene Sa Zur impfung verwendetes papillomavirus-e2- polypeptid
DE102008010954A1 (de) * 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
MX2011004292A (es) 2008-11-03 2011-05-31 Crucell Holland Bv Metodo para la produccion de vectores adenovirales.
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
EA023816B1 (ru) 2010-02-15 2016-07-29 Круселл Холланд Б.В. СПОСОБ ПРОДУЦИРОВАНИЯ ВИРУСНЫХ ЧАСТИЦ Ad26
WO2012020871A1 (ko) * 2010-08-13 2012-02-16 주식회사 제넥신 사람 파필로마바이러스 변형체 및 면역 증강제를 포함하는 자궁경부암 예방 또는 치료용 조성물
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
EP2601968A1 (en) * 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum HPV derived polynucleic acids for therapy
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
WO2016034678A2 (en) 2014-09-03 2016-03-10 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
PL3215187T3 (pl) 2014-11-04 2019-04-30 Janssen Vaccines & Prevention Bv Szczepionki terapeutyczne HPV16
AU2016309743B2 (en) * 2015-08-20 2019-02-07 Janssen Vaccines & Prevention B.V. Therapeutic HPV18 vaccines
CN109922829A (zh) * 2016-05-02 2019-06-21 扬森疫苗与预防公司 治疗性hpv疫苗组合

Also Published As

Publication number Publication date
JP2017534286A (ja) 2017-11-24
TWI731654B (zh) 2021-06-21
US10555996B2 (en) 2020-02-11
AR102527A1 (es) 2017-03-08
MA46378A (fr) 2019-08-07
NZ730802A (en) 2021-12-24
MA40902A (fr) 2017-09-13
MY181175A (en) 2020-12-21
LT3215187T (lt) 2018-12-27
ES2697903T3 (es) 2019-01-29
SA517381457B1 (ar) 2021-03-11
HRP20181895T1 (hr) 2019-01-11
TW202043476A (zh) 2020-12-01
US20170281747A1 (en) 2017-10-05
EP3421046A1 (en) 2019-01-02
TWI694147B (zh) 2020-05-21
RS58080B1 (sr) 2019-02-28
PL3215187T3 (pl) 2019-04-30
PT3215187T (pt) 2018-11-27
TW201617450A (zh) 2016-05-16
CA2965562C (en) 2023-11-21
CA2965562A1 (en) 2016-05-12
US20200164057A1 (en) 2020-05-28
AU2018282463A1 (en) 2019-01-24
CL2017001089A1 (es) 2017-12-29
JP2018148890A (ja) 2018-09-27
SI3215187T1 (sl) 2019-02-28
CN107075521B (zh) 2021-06-08
AU2018282463B2 (en) 2020-09-10
AU2015341926B2 (en) 2018-09-27
US10071151B2 (en) 2018-09-11
BR112017009177A2 (pt) 2018-12-11
EP3215187B1 (en) 2018-08-29
US11040096B2 (en) 2021-06-22
US9701721B2 (en) 2017-07-11
MX2017005788A (es) 2017-08-02
EP3215187A1 (en) 2017-09-13
ZA201703055B (en) 2019-11-27
EA035461B1 (ru) 2020-06-19
DK3215187T3 (en) 2018-12-10
IL251895B (en) 2019-08-29
AU2015341926A1 (en) 2017-04-27
JP6606571B2 (ja) 2019-11-13
JP6325751B2 (ja) 2018-05-16
HUE040440T2 (hu) 2019-03-28
EA201790976A1 (ru) 2017-09-29
KR20170083562A (ko) 2017-07-18
MA40902B1 (fr) 2018-12-31
CN107075521A (zh) 2017-08-18
SG11201702997YA (en) 2017-05-30
US20160122396A1 (en) 2016-05-05
WO2016071306A1 (en) 2016-05-12
US20180344841A1 (en) 2018-12-06
MD3215187T2 (ro) 2019-02-28
CO2017004838A2 (es) 2017-07-28
IL251895A0 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
CY1121377T1 (el) Θεραπευτικα εμβολια hpv16
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
AU2019283892A1 (en) Anti-human papillomavirus 16 E7 T cell receptors
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
MX2017011796A (es) Lo nuevo complejo que comprende un peptido de penetracion celular, una molecula cargo y un agonista peptidico de tlr.
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
AU2017297757A1 (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
MX2021010354A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
NZ725079A (en) Transgene genetic tags and methods of use
EA201890796A1 (ru) Новое антитело к мезотелину и содержащая его композиция
EA202090149A1 (ru) Антигенсвязывающие белки против вируса папилломы человека (hpv) и способы их применения
MX2017000838A (es) Cepa de listeria recombinante que expresa proteinas de fusion con antigenos heterologos y metodos para el uso de estas.
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
MX2019000215A (es) Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.
PE20191786A1 (es) Anticuerpo monoclonal para pd-l1
MX2019003156A (es) Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika.
WO2016116905A9 (en) Cmv antigens and uses thereof
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
EA201691981A1 (ru) Улучшенные транспортные молекулы модулярного антигена и их применение
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
MX363149B (es) Vacunas de nucleoproteina de la influenza.
MX2019007924A (es) Vacunas contra la influenza.
WO2018102774A8 (en) Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein a
WO2013138259A3 (en) Polypeptides for treating and/or limiting influenza infection
PH12018501532A1 (en) Cancer vaccines